insights_auto
Why is ALNY down 4.96%?
Dive Deeperchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$219.72
arrow_downward
-4.96%(-11.46) 1D
$220.98
arrow_upward
+0.57% (+1.26)bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$231.31
High
$231.36
Low
$219.40
Mkt. cap
29.40B
Avg. vol.
1.55M
Volume
1.66M
P/E ratio
37.40
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
Open
$231.31
High
$231.36
Low
$219.40
Mkt. cap
29.40B
Avg. vol.
1.55M
Volume
1.66M
P/E ratio
37.40
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
Simply Wall Street
·
2 days ago
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49%
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.